A patient with TP53 germline mutation developed Bowen's disease and myelodysplastic syndrome with myelofibrosis after chemotherapy against ovarian cancer

Kageaki Kuribayashi, Takuya Matsunaga, Toshio Sakai, Yuko Wada, Kumiko Tateno, Kazuyuki Murase, Akihito Fujimi, Rishu Takimoto, Takeshi Terui, Junji Kato, Aya Sasaki, Masaaki Satoh, Yoshiro Niitsu

研究成果: Article

7 引用 (Scopus)

抜粋

Here we report a case of myelodysplastic syndrome (MDS) with myelofibrosis associated with Bowen's disease. A female patient had undergone an operation and chemotherapy for ovarian cancer when she was 65 years old, and she developed MDS at the age of 70 years old. PCR-single strand conformation polymorphism (SSCP) analysis of peripheral blood mononuclear cells, a Bowen's disease lesion, and normal skin showed an abnormal peak in TP53 exon5. Direct sequencing revealed that they all had missense mutation in codon 175 (G to A) of arginine switched to histidine, suggesting a germline mutation of TP53. It was speculated that p53 function was lost by TP53 germline mutation with the loss of a wild type allele induced by the chemotherapy against ovarian cancer, leading to the development of MDS. No therapeutic effects of low dose melphalan or cyclosporine A on MDS were observed, however one month of 30 mg/ day prednisolone administration induced a hematological response.

元の言語English
ページ(範囲)490-495
ページ数6
ジャーナルInternal Medicine
44
発行部数5
DOI
出版物ステータスPublished - 2005 5 1

    フィンガープリント

ASJC Scopus subject areas

  • Internal Medicine

これを引用

Kuribayashi, K., Matsunaga, T., Sakai, T., Wada, Y., Tateno, K., Murase, K., Fujimi, A., Takimoto, R., Terui, T., Kato, J., Sasaki, A., Satoh, M., & Niitsu, Y. (2005). A patient with TP53 germline mutation developed Bowen's disease and myelodysplastic syndrome with myelofibrosis after chemotherapy against ovarian cancer. Internal Medicine, 44(5), 490-495. https://doi.org/10.2169/internalmedicine.44.490